‘Do we decide who lives based on economics?’ asks CF patient

Michael Twomey, a 44-year-old father to a seven-year-old boy, has the gene mutation that Orkambi was designed for, but has not been able to access the drug.

“I have not had the opportunity to see if it would benefit me,” he says.

Michael, who has cystic fibrosis (CF), lost a sister to the disease almost 20 years ago when she was just 29.